Article Text

Download PDFPDF

2022-RA-1515-ESGO Impact of surgical staging on survival of low grade endometrioid ovarian cancer apparently confined to the ovary
  1. Nicolò Bizzarri1,
  2. Majdi Imterat2,
  3. Robert Fruscio3,
  4. Anna Myriam Perrone4,
  5. Rosanna Mancari5,
  6. Alexander Traut2,
  7. Andrea Rosati1,
  8. Andreas du Bois2,
  9. Debora Ferrari3,
  10. Pierandrea de Iaco4,
  11. Raffaella Ergasti1,
  12. Beyhan Ataseven2,6,
  13. Silvia Volontè3,
  14. Marco Tesei4,
  15. Maria Teresa Perri1,
  16. Florian Heitz2,7,
  17. Nicole Concin2,
  18. Francesco Fanfani1,
  19. Enrico Vizza5,
  20. Giovanni Scambia1,
  21. Philipp Harter2 and
  22. Anna Fagotti1
  1. 1UOC Ginecologia Oncologica, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Dipartimento per la Salute della Donna e del Bambino e della Salute Pubblica, Rome, Italy
  2. 2Department of Gynecology and Gynecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany
  3. 3Clinic of Obstetrics and Gynecology, University of Milan Bicocca, San Gerardo Hospital, Monza, Italy
  4. 4Division of Oncologic Gynecology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
  5. 5Gynecologic Oncology Unit, IRCCS – Regina Elena National Cancer Institute, Rome, Italy
  6. 6Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
  7. 7Department for Gynecology with the Center for Oncologic Surgery Charité Campus Virchow-Klinikum, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany


Introduction/Background To assess the disease-free survival (DFS) of patients with low-grade endometrioid ovarian cancer apparently confined to the ovary, according to surgical staging. Secondary endpoint was to evaluate the DFS according to adjuvant chemotherapy.

Methodology Multicenter, retrospective, observational cohort study. Patients with endometrioid ovarian carcinoma, surgical procedure performed between 05/1985–12/2019, stage pT1 N0/N1/Nx Grade 1–2 were included. Patients were stratified according to completeness of surgical staging (complete defined as peritoneal and retroperitoneal staging), lymphadenectomy (defined as removal of any lymph node (LN) versus no LN assessment), and receipt of adjuvant chemotherapy.

Results 298 patients were included in the study period. 166 (55.7%) patients underwent complete surgical staging, and 199 (66.8%) patients underwent LN assessment (of these, 166 -83.4%- had unilateral/bilateral pelvic and para-aortic/caval lymphadenectomy). 11 (5.5%) patients of those undergoing LN assessment showed pathologic metastatic LNs (FIGO-stage IIIA1). 9/11 (81.8%) were diagnosed with grade 2 endometrioid ovarian cancer. 155 (52.0%) underwent adjuvant chemotherapy. Median follow up time was 45 months (95%CI:37.5–52.5). 5-year DFS and overall survival of the entire cohort were 89.8% and 96.2%, respectively. Patients undergoing complete surgical staging had a trend toward a better 5-year DFS comparing to incomplete surgical staging (92.4% versus 86.5%, respectively;p=0.051). Performance of lymphadenectomy (sampling/systematic) was associated with better 5-year DFS compared to no lymphadenectomy (91.9% versus 85.6%, respectively;p=0.016) (figure 1). Adjuvant chemotherapy did not impact 5-year DFS (p=0.552). At univariate analysis the only significant variable affecting DFS was the performance of lymphadenectomy (HR:0.388; 95%CI:0.174–0.866;p=0.021).

Abstract 2022-RA-1515-ESGO Figure 1

Conclusion In a retrospective multicenter series of low-grade endometrioid ovarian cancers apparently confined to the ovary, lymphadenectomy appeared to be associated with improved DFS. Adjuvant chemotherapy did not impact DFS. Nevertheless, the present results derive from a retrospective uncontrolled study, in which the indication for or against lymphadenectomy/adjuvant chemotherapy was not prospectively defined, causing potential significant selection bias.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.